Insights

Innovative Precision Medicine STALICLA's development of a neurodevelopmental disorder-specific precision medicine platform in autism spectrum disorder presents opportunities for personalized drug development collaborations, clinical trial partnerships, and targeted therapeutics supply.

Strategic Industry Collaborations Partnerships with research institutes like the National Institute of Drug Abuse highlight potential avenues for sales of clinical trial technologies, data management solutions, and research support services to facilitate Phase 3 trials for substance use disorders.

Funding and Expansion Recent financing rounds secured over CHF 2 million and strategic leadership hires suggest ongoing expansion plans, creating opportunities to offer clinical development support, specialized biotech services, or investment in innovative therapeutic platforms.

Technological Edge Utilization of advanced tech stacks including AWS, Optimizely, and Modernizr indicates STALICLA’s focus on cutting-edge data and digital solutions, providing potential sales channels for cloud infrastructure, digital engagement tools, and analytical software tailored for biotech R&D.

Market Positioning As a pioneering Swiss biopharma with a focus on neuropsychiatric disorders and evolving clinical pipelines, STALICLA offers opportunities for early access partnerships, licensing deals, and strategic alliances targeting neurodevelopmental and neuropsychiatric treatment markets.

STALICLA Tech Stack

STALICLA uses 8 technology products and services including Optimizely, UsableNet, Sovrn, and more. Explore STALICLA's tech stack below.

Optimizely

A/B Testing

UsableNet

Accessibility

Sovrn

Advertising

Taboola

Advertising

gstatic.com

Content Delivery Network

Cloudflare

Content Management System

Video.js

Javascript Libraries

Wunderkind

Marketing Automation

STALICLA Email Formats	Example	Percentage
First.Last@stalicla.com	John.Doe@stalicla.com	97%
LF@stalicla.com	DJ@stalicla.com	3%

STALICLA Email Formats

Example

Percentage

First.Last@stalicla.com

John.Doe@stalicla.com

97%

LF@stalicla.com

DJ@stalicla.com

Frequently Asked Questions

What is STALICLA's official website and social media links?

STALICLA's official website is stalicla.com and has social profiles on LinkedIn Crunchbase.

What is STALICLA's SIC code NAICS code?

STALICLA's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does STALICLA have currently?

As of July 2026, STALICLA has approximately 23 employees across 3 continents, including EuropeAfricaNorth America. Key team members include Ceo And Founder: L. D.Cto, Head Of Discovery And Data Science: E. G.Head Of Clinical Operations: E. P.. Explore STALICLA's employee directory with LeadIQ.

What industry does STALICLA belong to?

STALICLA operates in the Biotechnology Research industry.

What technology does STALICLA use?

STALICLA's tech stack includes OptimizelyUsableNetSovrnTaboolagstatic.comCloudflareVideo.jsWunderkind.

What is STALICLA's email format?

STALICLA's email format typically follows the pattern of First.Last@stalicla.com. Find more STALICLA email formats with LeadIQ.

How much funding has STALICLA raised to date?

As of July 2026, STALICLA has raised $56M in funding. The last funding round occurred on Jun 30, 2025 for $2.5M.

When was STALICLA founded?

STALICLA was founded in 2017.

STALICLA

Q: What is STALICLA's official website and social media links?

STALICLA's official website is stalicla.com. STALICLA has social profiles on LinkedIn.

Q: How many employees does STALICLA have currently?

STALICLA has approximately 23 employees.

Q: What technology does STALICLA use?

STALICLA's tech stack includes HTTP/3, Cloudflare, AppNexus, Google Analytics Enhanced eCommerce, Smart AdServer.

Q: What is STALICLA's NAICS code?

STALICLA's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchGeneva, Switzerland11-50 Employees

STALICLA is a Swiss clinical-stage biotechnology company focusing on Neuro Precision Medicine for neurodevelopmental and neuropsychiatric disorders. It aims to tailor therapies to specific patient subgroups, such as those with autism spectrum disorder, using an integrated, multi-omics approach to identify candidate drugs, with STP1 advancing toward Phase 2 trials. In the realm of Substance Use Disorder, the company collaborates with the National Institute on Drug Abuse (NIDA) to move STP7, for cocaine use disorder, into Phase 3 trials. Based in Geneva, Switzerland, STALICLA operates in the biotechnology research sector, pursuing precision medicines for brain disorders.

As a small to mid-sized biotech company, it sits within the Swiss life sciences landscape focusing on neurodevelopmental and neuropsychiatric indications with a pipeline spanning Phase 2 and Phase 3 trials. Recent leadership developments include the appointment of Dr. Purnanand Sarma as Chair of the Board in July 2024.

Insights

Similar companies to STALICLA

Neuren Pharmaceuticals

Ovid Therapeutics

STALICLA Tech Stack

Media & News

Stalicla Sa receives financing of $2.51M in financing.

Stalicla Sa hires Tim Dyer as Chairman.

Stalicla Sa hired Paulo Fontoura as Chief Scientific and Clinical Development Advisor on Sep 19th '24.

Stalicla Sa hired Purnanand Sarma as Chair of the Board of Directors on Jul 9th '24.

Stalicla Sa hires Thomas Blaettler as MD.

Evgen Limited partnered with Stalicla Sa on Oct 1st '22.

Stalicla Sa launches neurodevelopmental disorder-specific precision medicine platform.

STALICLA's Email Address Formats